Hypertention: The "revenge" of cancer and high blood pressure

With the aging of the population, hypertension is becoming a serious global problem.
the incidence of hypertension has doubled in the past 40 years, according to epidemiological data.
, the incidence of hypertension and related cardiovascular events is increasing worldwide, with 7.6 million deaths worldwide each year.
, on the other hand, an ageing population has contributed significantly to cancer becoming a worldwide public health problem.
cancer is the leading cause of death worldwide, with 24.5 million new cases and 9.6 million deaths worldwide in 2017.
, the use of small molecule inhibitors for cancer treatment significantly improved the prognostication of cancer patients and extended their survival.
cardiovascular disease is the leading cause of late onset and death in cancer survivors.
, the concept of "oncology cardiology" was proposed to emphasize only the importance of prevention, diagnosis, treatment and follow-up of heart dysfunction associated with cancer treatment.
recently, experts from the cardiovascular field recently introduced a new sub-specialty in the journal Hypertension, Tumor Hypertension, which focuses on complex pathophysiological studies of hypertension and tumors.
this paper mainly discusses whether the occurrence of hypertension pre-tumor, how anti-cancer treatment affects the blood pressure level of patients, and what is appropriate for such patients to control blood pressure.
Hypertension is a potential risk factor for cancer In a team of 577,799 adults, it was found that men's medium blood pressure (defined as the average of systolic and espressopressury) was associated with a higher risk of cancer (per 10 mmHg increment, HR=1.07), but the relationship did not exist in women.
Recent epidemiological studies have shown that high blood pressure is associated with higher risks of renal cell carcinoma (RCC), colon cancer, esophageal squamous cell carcinoma (SCC), head and neck cancer, skin SCC, post menovascular breast cancer and uterine adenocarcinoma.
common risk factors for high blood pressure and cancer, including obesity, diabetes, excessive sodium intake, and low physical activity, may mask a causal link between high blood pressure and cancer.
addition, the results of studies on the relationship between hypertension and cancer vary depending on the type and location of the cancerous society.
a systematic review of 27 observational studies on the occurrence of antidepressants and cancer found that diuretic use was associated with an increased risk of kidney cancer (RR=1.34) and that the risk increased with the duration of treatment.
, the association remained significant after adjusting for high blood pressure and smoking.
meta-analysis, which included nine observational studies, found that the risk of skin cancer was associated with the use of pyridyl.
, the use of ACE inhibitors was 14% higher than the use of ARB.
However, the association between the use of ARB or ACE inhibitors and cancer risk may be due to a lack of control over confluent factors such as smoking and environmental exposure, lack of long-term data, and significant heterogeneity among the study population.
some cancer-induced hypertension studies have shown that excessive expression of some vascular active peptides in the cancerous system of human kidney cells, including uremia II., epinephrine and endotycin, can lead to elevated blood pressure in RCC patients.
, the occurrence of hypertension is also more obvious in patients with sub-tumor syndrome and hepatocellular carcinoma, suggesting that certain types of cancer itself can also cause hypertension.
hypertension caused by anti-cancer treatment is the most common complication (38%) in cancer patients, and a higher proportion of patients with high blood pressure, older age, and higher body mass index.
, veGF signal path path (VSP) inhibitors have the effect of inhibiting tumor progression and metastasis.
because veGF signal path inhibitors have a boost effect, so it inevitably triggered the occurrence of hypertension.
patients can quickly improve their symptoms after stopping.
, anti-micro-tube drugs, alkyl samples and alkyl agents have been reported to have the effect of raising blood pressure in cancer patients.
but no studies have confirmed that ≥ two anti-cancer drugs have a synergy with elevated blood pressure.
blood pressure control strategies in cancer patients with the disease have expert advice that systolic/lysopressuric pressure should be maintained at .lt;140/90 mm Hg in patients taking VSP inhibitors.
, blood pressure should be measured once a week during the first treatment cycle and then at least every 2 to 3 weeks.
a recent review by the American College of Cardiology (AHA), antihypertensive drugs are recommended for cancer patients with systolic/throopressid pressure ≥130/80 mm Hg.
same time, the European Society of Cardiology/European Society of Hypertension (EHA) guidelines for hypertension recommend measuring blood pressure once a week during the first cycle of chemotherapy, at least every 2 to 3 weeks thereafter.
As far as antihypertensive therapy is involved, there are currently no specific antihypertensive drugs recommended for hypertension associated with the use of VEGF signaling pathline inhibitors, calcium antagonists of bihydrohydrocarbons or first-line drugs that can be used to treat antihypertensive drugs in cancer patients, and studies have shown that they can help reduce beva monoantion-related hypertension.
, the article systematically describes the close relationship between hypertension and cancer.
mechanisms for understanding changes in blood pressure in cancer patients will help identify new treatment targets for patients with high blood pressure.
: Kidoguchi S, Sugano N, Tokudome G, Yokoo T, Yano Y, Hatake K, Nishiyama A. New Concept of Onco-Hypertension and Future Perspectives. Hypertension. 2021 Jan; 77(1):16-27. doi: 10.1161/HYPERTENSIONAHA.120.16044.MedSci Original Source: MedSci Original Copyright Notice: All noted on this website "Source: Met Medical" or "Source: MedSci Original" text, images and audio and video materials, copyrights are owned by Metz Medical, without authorization, no media, website or individual may reproduce, authorized to reproduce with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here